Damora Therapeutics, Inc., a clinical-stage biotechnology company, develops molecule therapeutics for the treatment of fibrosis, cancer, inflammation, and other related diseases. It develops GB3226, a preclinical small molecule dual inhibitor of ENL-YEATS and FLT3 and GB1211, an oral small molecule inhibitor of galectin-3 to treat multiple types of oncology and liver disease indications. The company was founded in 2011 and is headquartered in Copenhagen, Denmark.
Frequently asked questions
What sector does Galecto Inc (GLTO) operate in?
Galecto Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Galecto Inc (GLTO) current stock price?
As of the latest data, Galecto Inc stock price is $24.45, with a previous close of $24.45.
What is Galecto Inc (GLTO) current market capitalization?
Galecto Inc market cap is approximately 1.47 billion.
What is Galecto Inc (GLTO) Earnings Per Share (EPS)?
The trailing EPS is -$12.11, and the forward EPS is -$1.07.
Does Galecto Inc (GLTO) pay dividends?
No. Galecto Inc does not pay a dividend.
What is Galecto Inc (GLTO) beta (volatility) score?
Galecto Inc has a beta of 1.572, suggesting it is more volatile than the market.